Pulmicort®
Budesonide is an ICS for maintenance treatment of asthma and prevention of exacerbations. Available as nebulizer suspension and dry powder inhaler.
| Dosage Form | Nebulizer Suspension / DPI Inhaler |
| Strength | 0.25 mg/2mL, 0.5 mg/2mL, 1 mg/2mL (nebulizer); 90, 180 mcg (DPI) |
| Storage | Store at 20–25°C upright. Protect from light. Open envelope: use within 2 weeks. |
| Category | Respiratory |
| Availability | Available for Transfer |
Asthma (maintenance therapy in children and adults); croup (off-label).
Glucocorticoid that activates intracellular glucocorticoid receptors, translocates to the nucleus, and modulates gene transcription to reduce airway inflammation, mucus production, and hyperresponsiveness.
Each Burrard Pharmaceuticals technology transfer package for Budesonide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.